The mortality and morbidity associated with stroke makes the development of new drugs a research priority. Recent unsuccessful clinical trials have reduced enthusiasm for the development of neuroprotective drugs. Here, we use empirical evidence derived from systematic reviews of stroke drug development to identify stages of drug development which might be improved. We then propose exemplar strategies which may be helpful, along with some basic economic modelling of what the impact of such strategies might be. This suggests that relatively straightforward measures might reduce the costs of drug development by $5.8 bn or 31%.
SudlowC.L.WarlowC.P.Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke1997; 28:491–9.
2.
TaylorT.N.DavisP.H.TornerJ.C.HolmesJ.MeyerJ.W.JacobsonM.F.Lifetime cost of stroke in the United States. Stroke1996; 27:1459–66.
3.
CadilhacD.A.CarterR.ThriftA.G.DeweyH.M.Estimating the long-term costs of ischemic and hemorrhagic stroke for Australia: new evidence derived from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke2009; 40:915–21.
4.
SakaO.McGuireA.WolfeC.Cost of stroke in the United Kingdom. Age Ageing2009; 38:27–32.
Van der WorpH.B.HowellsD.W.SenaE.S.Can animal models of disease reliably inform human studies?PLoS Med2010; 7:e1000245.
7.
HowellsD.W.PorrittM.J.RewellS.S.Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab2010; 30:1412–31.
8.
O'CollinsV.E.MacleodM.R.DonnanG.A.HorkyL.L.Van der WorpB.H.HowellsD.W.1026 experimental treatments in acute stroke. Ann Neurol2006; 59:467–77.
9.
GilliganA.K.ThriftA.G.SturmJ.W.DeweyH.M.MacdonellR.A.DonnanG.A.Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit?Cerebrovasc Dis2005; 20:239–44.
SenaE.S.BriscoeC.L.HowellsD.W.DonnanG.A.SandercockP.A.MacleodM.R.Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab2010; 30:1905–13.
13.
MacleodM.R.Van der WorpH.B.SenaE.S.HowellsD.W.DirnaglU.DonnanG.A.Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke2008; 39:2824–9.
14.
SenaE.WhebleP.SandercockP.MacleodM.Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke2007; 38:388–94.
15.
SenaE.S.Van der WorpH.B.BathP.M.HowellsD.W.MacleodM.R.Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol2010; 8:e1000344.
16.
MacleodM.R.FisherM.O'CollinsV.Good laboratory practice: preventing introduction of bias at the bench. Stroke2009; 40:e50–2.
17.
KilkennyC.BrowneW.J.CuthillI.C.EmersonM.AltmanD.G.Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol2010; 8:e1000412.
18.
O'CollinsV.E.MacleodM.R.CoxS.F.Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing. J Cereb Blood Flow Metab2011; 31:962–75.
19.
DonnanG.A.The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke2008; 39:242–8.
20.
SenaE.Van der WorpH.B.HowellsD.MacleodM.How can we improve the pre-clinical development of drugs for stroke?Trends Neurosci2007; 30:433–9.
21.
BathP.M.MacleodM.R.GreenA.R.Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke2009; 4:471–9.
22.
Van der WorpH.B.SenaE.S.DonnanG.A.HowellsD.W.MacleodM.R.Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis.Brain2007; 130(Pt 12):3063–74.
23.
MacleodM.R.O'CollinsT.HorkyL.L.HowellsD.W.DonnanG.A.Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res2005; 38:35–41.
